Prognosis in Patients With Sentinel Node-Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria

Humboldt-Universität zu Berlin, Berlín, Berlin, Germany
Journal of Clinical Oncology (Impact Factor: 18.43). 06/2011; 29(16):2206-14. DOI: 10.1200/JCO.2010.31.6760
Source: PubMed

ABSTRACT Prognosis in patients with sentinel node (SN)-positive melanoma correlates with several characteristics of the metastases in the SN such as size and site. These factors reflect biologic behavior and may separate out patients who may or may not need additional locoregional and/or systemic therapy.
Between 1993 and 2008, 1,080 patients (509 women and 571 men) were diagnosed with tumor burden in the SN in nine European Organisation for Research and Treatment of Cancer (EORTC) melanoma group centers. In total, 1,009 patients (93%) underwent completion lymph node dissection (CLND). Median Breslow thickness was 3.00 mm. The median follow-up time was 37 months. Tumor load and tumor site were reclassified in all nodes by the Rotterdam criteria for size and in 88% by the Dewar criteria for topography.
Patients with submicrometastases (< 0.1 mm in diameter) were shown to have an estimated 5-year overall survival rate of 91% and a low nonsentinel node (NSN) positivity rate of 9%. This is comparable to the rate in SN-negative patients. The strongest predictive parameter for NSN positivity and prognostic parameter for survival was the Rotterdam-Dewar Combined (RDC) criteria. Patients with submicrometastases that were present in the subcapsular area only, had an NSN positivity rate of 2% and an estimated 5- and 10-year melanoma-specific survival (MSS) of 95%.
Patients with metastases < 0.1 mm, especially when present in the subcapsular area only, may be overtreated by a routine CLND and have an MSS that is indistinguishable from that of SN-negative patients. Thus the RDC criteria provide a rational basis for decision making in the absence of conclusions provided by randomized controlled trials.

Download full-text


Available from: Christiane A Voit, Sep 03, 2015
  • Source
    • "Microanatomic location of metastases is evaluated according to the criteria by Dewar et al. [15]. SN tumour burden is assessed according to the Rotterdam criteria for SN tumour burden [16] [17]. Final histology of the SN or LND was considered as the golden standard. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ultrasound guided fine needle aspiration cytology (US-guided FNAC) can identify microscopic involvement of lymph nodes as in breast cancer and avoid surgical sentinel node (SN). Its utility in melanoma patients is controversial and subject of this study.
    European journal of cancer (Oxford, England: 1990) 07/2014; 50(13). DOI:10.1016/j.ejca.2014.05.027 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Selection for sentinel lymph node biopsy (SLNB) in cutaneous melanoma is currently based on histopathological variables specified in prognostic staging criteria. In 2009, these criteria were updated replacing Clark level with the tumour mitotic rate (TMR) when defining thin T1 tumours. This study aimed to determine the histopathological variables independently predictive of sentinel lymph node involvement and discusses which variables should influence our selection for SLNB. Methods One hundred and fifty-three patients with primary invasive localized cutaneous melanoma who underwent SLNB between 2003 and 2007 were reviewed from a prospectively collected database. We performed a multivariate binary logistic regression analysis to ascertain which variables independently predict sentinel status. Results SLNB positivity rate was 17.3%. No patient with a thin T1 tumour was SLNB positive. Breslow thickness was the only independent predictor of sentinel lymph node (SLN) status to reach significance (x 2, 10.555; p, 0.001). TMR and ulceration were not independent predictors of sentinel node status (x 2, 0.988; p, 0.320 and x 2, 2.082; p, 0.149, respectively). Conclusion Breslow thickness is the only variable that is consistently reported as an independent predictor of SLN status. The use of TMR and ulceration in staging criteria is intended to establish prognosis, not select for SLNB. Given the important implications of a positive SLNB on surgical management, accurate selection is imperative. Selection based solely on Breslow thickness, rather than staging criteria, may be valid. However, there is an urgent need for a well-designed large multi-centre analysis to validate this. Until then, we continue to select for SLNB within a multidisciplinary team accounting for multiple factors. Level of Evidence: Level II, Prognostic/Risk Study.
    European Journal of Plastic Surgery 10/2012; 35(10). DOI:10.1007/s00238-012-0714-2
  • Journal of Clinical Oncology 06/2011; 29(16):2137-41. DOI:10.1200/JCO.2010.34.1982 · 18.43 Impact Factor
Show more